Press Detail

/
PRESSEMITTEILUNG

Biotest reaches 2^nd milestone in Biotest Next Level expansion project

- Authorities grant building approval

- Relocation activities of laboratories and offices for production start in June

Dreieich, 22 June, 2017. Within the Biotest Next Level expansion project, Biotest will more than double its production capacity at the Dreieich site, invest over EUR 250 million and create around 300 new jobs. After completion of the shell construction of Biotest Next Level in October 2015, the second milestone was reached within the schedule with the building approval. This is a further step towards the complete commissioning of the new plant, which will start the regular operation in approximately 2 to 3 years and will still result in a considerable financial burden during its ramp-up.

The permit for the use of the building is the result of an intensive examination by the building inspectorate of the district of Offenbach (Bauaufsicht des Kreises Offenbach).

A prerequisite was, among other things, proof that the systems work perfectly in respect to safety, such as fire alarm systems, fire extinguishers and alarm systems - particularly the interaction of all technical components. Apart from the commitment of the entire project team, the key to success was the detailed planning of the preparations and the tests to be carried out in collaboration with authorities and experts.

As a result of the approval, relocation activities in the laboratory as well as the production offices will be carried out as planned in June 2017.

"By reaching this milestone, we have made a decisive step forward in achieving the goals of the company, and on behalf of the entire Board, I would like to thank the whole team for the great performance." stated Bernhard Ehmer, CEO of Biotest AG.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.